| association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a116 |
CHEK2_mut |
167 |
1 |
1 |
OSU-03012 |
PDPK1 (PDK1) |
5 |
866 |
2.77 |
1.92 |
4 |
2.08 |
1.7 * |
1.7 * |
1 * |
1.91e-05 |
1.95e-11 |
6.56e-03 |
2.7 |
a260 |
CHEK2_mut |
200 |
1 |
1 |
LAQ824 |
HDAC |
5 |
868 |
0.0237 |
-2.79 |
-0.706 |
2.08 |
1.7 * |
1.7 * |
0.97 . |
1.66e-04 |
6.38e-14 |
8.72e-01 |
11 |
a275 |
CHEK2_mut |
180 |
1 |
1 |
Thapsigargin |
sarco-endoplasmic reticulum Ca2+-ATPases |
5 |
852 |
-0.669 |
-3.89 |
-0.738 |
3.15 |
1.6 * |
1.6 * |
1 * |
1.9e-04 |
3.83e-04 |
6.87e-02 |
11 |
a410 |
CHEK2_mut |
182 |
1 |
1 |
Obatoclax Mesylate |
BCL2, BCL2L1, MCL1 |
5 |
859 |
2.77 |
-0.916 |
1.36 |
2.28 |
1.3 * |
1.3 * |
0.76 . |
4.92e-04 |
5.09e-14 |
2.97e-02 |
20 |
a477 |
CHEK2_mut |
133 |
1 |
1 |
Doxorubicin |
DNA intercalating |
5 |
867 |
0.0237 |
-1.77 |
0.852 |
2.62 |
1.6 * |
1.6 * |
1.2 * |
6.48e-04 |
5.31e-05 |
5.89e-02 |
22 |
